Table 5 Anastomotic complications in randomised trials comparing neo-adjuvant chemoradiation and surgery with surgery alone
Anastomotic complications neo-adjuvant chemoradiation and surgery vs. surgery alone | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Study | Groups no | CRT scheme | Surgery type | Anastomotic location | Anastomotic leakage | Anastomotic stenosis | ||||
CRT + S | S | Chemo | RT | CRT + S | S | CRT + S | S | |||
Nygaard et al. 1992 [23] | 34 | 38 | Cisplatin | 35.0 Gy (20 × 1.75) | TTE | Not mentioned | 6% | 3% | Not Mentioned | |
Le Prise et al. 1993 [24] | 41 | 45 | Cisplatin 5-FU | 20.0 Gy (10 × 2.0) | Not mentioned | Not mentioned | Not Mentioned | Not Mentioned | ||
Walsh et al. 1996 [25] | 58 | 55 | Cisplatin 5-FU | 40.0 Gy (15 × 2.67) | TTE or THE | Cervical | 3% | 4% | Not Mentioned | |
Bosset et al. 1997 [26] | 143 | 139 | Cisplatin | 37.0 Gy (10 × 3.7) | TTE >80% | Not mentioned | Not Mentioned | Not Mentioned | ||
Lee et al. 2004 [27] | 51 | 50 | Cisplatin 5-FU | 45.6 Gy (38 × 1.2) | TTE | Cervical | Not Mentioned | 14% | 17% | |
Urba et al. 2001 [28] | 50 | 50 | Cisplatin 5-FU Vinblastin | 45.0 Gy (30 × 1.5) | THE | Cervical | 15% | 8% | Not Mentioned | |
Burmeister et al. 2005 [29] | 128 | 128 | Cisplatin 5 FU | 35.0 Gy (15 × 2.3) | TTE | Thoracic or Cervival | 5% | 5% | 19% | 24% |
Tepper et al. 2008 [30] | 30 | 26 | Cisplatin 5-FU | 50.4 Gy (28 × 1.8) | TTE or THE | Not mentioned | Not Mentioned | Not Mentioned | ||
Van Hagen et al. 2012 [16] | 178 | 188 | Carboplatin Paclitaxel | 41.4 Gy (23 × 1.8) | TTE or THE | Cervical | 22% | 30% | Not Mentioned | |